Xellia Pharmaceuticals

Copenhagen, Denmark Founded: 1903 • Age: 123 yrs Acquired By Novo Holdings
Manufacturer of active pharmaceutical ingredients and finished dosage forms
Annual revenue $2.6M Latest available
Total funding - Funding intelligence
Employees 52 Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors - Brand Intelligence

About Xellia Pharmaceuticals

Xellia Pharmaceuticals is a company based in Copenhagen (Denmark) founded in 1903 was acquired by Novo Holdings in May 2013. The company has 52 employees as of April 06, 2024.

  • Headquarter Copenhagen, Denmark
  • Employees 52 as on 06 Apr, 2024
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Xellia Pharmaceuticals Private Limited
  • Date of Incorporation 13 Sep, 2010
  • Jurisdiction Bangalore, Karnataka, India
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $2.64 M (USD)
    22.19
    as on Mar 31, 2023
  • Net Profit
    $254.83 K (USD)
    24.4
    as on Mar 31, 2023
  • EBITDA
    $472.25 K (USD)
    5.14
    as on Mar 31, 2023
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    52

    as on Apr 06, 2024

  • Acquired by
    Novo Holdings

    (May 21, 2013)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

People of Xellia Pharmaceuticals

Headcount 1000-5000
Employee Profiles 87
Board Members and Advisors 5
Employee Profiles
People
Eva Blem
Senior Manager FP&A
People
Anders Dorph
Senior Director, Global Supply Chain
People
Klaudia Koczmann
Generalist People & Organization
People
Srihari Moudgal
Site Controller - India, FP&A

Unlock access to complete

Board Members and Advisors
people
Preben Haaning
Board Member

Unlock access to complete

Funding Insights of Xellia Pharmaceuticals

Premium access

Detailed funding history for Xellia Pharmaceuticals

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in Xellia Pharmaceuticals

Xellia Pharmaceuticals has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Novo Holdings.

All
Venture Fund
Investor Description Founded Year Domain Location
Private equity and venture capital fund focused on the healthcare sector
Locked Locked Locked
Premium access

Investor details for Xellia Pharmaceuticals

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Xellia Pharmaceuticals

Investments
Premium access

Investment portfolio details for Xellia Pharmaceuticals

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Xellia Pharmaceuticals

Premium access

Detailed financials for Xellia Pharmaceuticals

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Xellia Pharmaceuticals Comparisons

Xellia Pharmaceuticals Primary company
Description
Manufacturer of active pharmaceutical ingredients and finish...
Location
Copenhagen, Denmark
Founded Year
1903
Annual Revenue
$2.64 M (USD)
Net Profit
$254.83 K (USD)
EBITDA
$472.25 K (USD)
Employees
52
As of 2024
Premium access

Peer comparison for Xellia Pharmaceuticals

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Xellia Pharmaceuticals

Premium access

Detailed competitors of Xellia Pharmaceuticals

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Xellia Pharmaceuticals

Premium access

Complete news archive for Xellia Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Xellia Pharmaceuticals

Xellia Pharmaceuticals was founded in 1903.

Xellia Pharmaceuticals is headquartered in Copenhagen, Denmark.

As of Apr 06, 2024, the latest employee count at Xellia Pharmaceuticals is 52.

Annual revenue of Xellia Pharmaceuticals is $2.64M as on Mar 31, 2023.

Founded in 1903 and headquartered in Copenhagen, Denmark, Xellia Pharmaceuticals operates in the pharmaceutical sector with a focus on anti-infective therapies. Active pharmaceutical ingredients are supplied to companies worldwide, while finished dosage forms are provided mainly through contract manufacturing organizations. Research and development, manufacturing, and commercialization activities are conducted, with emphasis placed on sustainable practices for critical care treatments of serious infections.

Xellia Pharmaceuticals has 1 investor. Key investors include Novo Holdings.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available